Drug intelligence / Profile preview

TUR01

Development stage: Phase 1
Lead developer: Turgut Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

TUR01 is an adalimumab biosimilar candidate developed by Turgut İlaçları. It is a monoclonal antibody that inhibits tumor necrosis factor-α (TNF-α). Stability studies have shown that the drug substance and drug product maintain long-term stability under different temperature conditions. According to research, TUR01 can be safely refrigerated at 5 ± 3°C for 24 months, and if the cold chain is broken, the product will remain stable at room temperature for 2 months[1].

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on TUR01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TUR01.

Explore the full profile